시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 당뇨병성 황반부종(DME) 시장 보고서(2025년)
Diabetic Macular Edema (DME) Global Market Report 2025
상품코드 : 1720779
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

당뇨병성 황반부종(DME) 시장 규모는 향후 수년간 안정된 성장이 전망될 예정입니다. 예측 기간의 성장은 치료에 대한 원격 의료 채택 확대, 당뇨병 안과 전문 의료 센터의 확대에 기인합니다. 주요 동향으로는 항VEGF 요법의 개발, 코르티코스테로이드 임플란트의 채용, 약물전달 시스템의 발전, 망막 레이저 치료의 혁신, AI를 탑재한 진단 툴, 저침습 수술 수술의 사용 증가 등을 들 수 있습니다.

당뇨병의 유병률 상승은 당뇨병성 황반부종(DME) 시장의 성장을 가속할 것으로 예측됩니다. 당뇨병 황반 부종은 망막 혈관을 손상시켜 황반부에 액체를 누출시켜 부종을 가져옵니다. 예를 들어, 2023년 6월 미국의 공중 보건 연구 기관인 건강 측정 및 평가 연구소는 전 세계적으로 5억 명이 넘는 사람들이 당뇨병을 앓고 있다고 보고했습니다.

당뇨병 황반 부종(DME) 치료 부문의 주요 기업은 환자 관리 및 치료 성과를 높이기 위해 특히 약물 요법의 기술적 진보를 중시하고 있습니다. 예를 들어, 2022년 3월 스위스에 본사를 둔 제약 회사인 노바티스 AG는 당뇨병성 황반부종(DME)으로 인한 시각 장애 치료제로 베오뷰가 유럽 집행위원회로부터 승인을 받았다고 발표했습니다. 이번 승인은 베오뷰가 1년 동안 시력 개선에 있어 아플리버셉트와 유사한 효과를 입증한 임상 3상 KESTREL 및 KITE 연구 결과를 바탕으로 이루어졌습니다. 또한, 베오뷰로 치료받은 환자의 절반 이상이 12주 치료 일정을 유지했으며, 아플리버셉트로 치료받은 환자에 비해 망막액 발생 사례가 더 적었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Diabetic macular edema (DME) is a diabetes-related complication characterized by fluid accumulation in the macula, the central part of the retina responsible for sharp vision. This swelling occurs due to damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or potential blindness if left untreated. DME is a leading cause of vision loss among diabetic patients and is closely linked to diabetic retinopathy.

The primary treatments for diabetic macular edema (DME) include anti-VEGF therapy, corticosteroids, laser therapy, and surgical intervention. Anti-VEGF therapy works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and retinal leakage, contributing to DME. The disease progresses through different stages, including early, moderate, and advanced stages. Patient demographics are categorized by age groups, including adults, the elderly, and children. Routes of administration include intravitreal injection, topical application, and systemic methods, with distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The diabetic macular edema (DME) market research report is one of a series of new reports from The Business Research Company that provides diabetic macular edema (DME) market statistics, including the diabetic macular edema (DME) industry's global market size, regional shares, competitors with a diabetic macular edema (DME) market share, detailed diabetic macular edema (DME) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic macular edema (DME) industry. This diabetic macular edema (DME) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic macular edema (DME) market size has grown steadily in recent years. It will grow from $4.67 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to the rise in the prevalence of diabetes, an increase in edema-related disorders, the growing prevalence of diabetic eye diseases, a surge in the geriatric population, and an increase in cases of blindness.

The diabetic macular edema (DME) market size is expected to see steady growth in the next few years. It will grow to $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth during the forecast period is driven by improved healthcare access, increased government healthcare funding, greater awareness of diabetic complications, the growing adoption of telemedicine for eye care, and the expansion of specialized diabetic eye care centers. Key trends include the development of anti-VEGF therapies, the adoption of corticosteroid implants, advancements in drug delivery systems, innovations in retinal laser treatments, AI-powered diagnostic tools, and the increasing use of minimally invasive surgical techniques.

The rising prevalence of diabetes is anticipated to propel the growth of the diabetic macular edema (DME) market. Factors such as sedentary lifestyles, unhealthy dietary habits, increasing obesity rates, aging populations, and genetic predisposition contribute to the growing incidence of diabetes. This condition leads to diabetic macular edema by damaging retinal blood vessels, causing fluid leakage into the macula and resulting in swelling. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes. This number is projected to more than double, reaching 1.3 billion by 2050. Consequently, the increasing prevalence of diabetes is driving the expansion of the diabetic macular edema (DME) market.

Leading companies in the diabetic macular edema (DME) treatment sector are emphasizing technological advancements, particularly in drug therapies, to enhance patient management and treatment outcomes. These advanced drug therapies incorporate innovative technologies and research to improve treatment efficacy, minimize side effects, and provide better results for patients. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced the European Commission's approval of Beovu for treating visual impairment caused by diabetic macular edema (DME). This approval was based on Phase III KESTREL and KITE study findings, which demonstrated Beovu's comparable effectiveness to aflibercept in improving vision over a one-year period. Additionally, more than half of the patients treated with Beovu maintained a 12-week treatment schedule, experiencing fewer instances of retinal fluid compared to those treated with aflibercept.

In July 2024, Merck & Co Inc, a US-based pharmaceutical company, acquired Eyebiotech Limited for $1.3 billion. This acquisition strengthens Merck & Co.'s portfolio, enhances research capabilities, and provides access to Restoret (EYE-103), a promising treatment for diabetic macular edema (DME) and treatment-naive neovascular age-related macular degeneration (AMD). Through this acquisition, the company aims to address significant unmet needs in ophthalmology. Eyebiotech Limited (EyeBio) is a UK-based biotechnology company specializing in ophthalmology.

Major players in the diabetic macular edema (dme) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., and Allergan plc.

North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic macular edema (DME) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic macular edema (DME) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic macular edema (DME) market consists of revenues earned by entities by providing services such as retinal imaging, fluorescein angiography, visual acuity testing, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic macular edema market includes sales of ranibizumab, aflibercep, fluocinolone acetonide intravitreal implant, and dexamethasone intravitreal implant. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Macular Edema (DME) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic macular edema (dme) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for diabetic macular edema (dme) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic macular edema (dme) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Diabetic Macular Edema (DME) Market Characteristics

3. Diabetic Macular Edema (DME) Market Trends And Strategies

4. Diabetic Macular Edema (DME) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Macular Edema (DME) Growth Analysis And Strategic Analysis Framework

6. Diabetic Macular Edema (DME) Market Segmentation

7. Diabetic Macular Edema (DME) Market Regional And Country Analysis

8. Asia-Pacific Diabetic Macular Edema (DME) Market

9. China Diabetic Macular Edema (DME) Market

10. India Diabetic Macular Edema (DME) Market

11. Japan Diabetic Macular Edema (DME) Market

12. Australia Diabetic Macular Edema (DME) Market

13. Indonesia Diabetic Macular Edema (DME) Market

14. South Korea Diabetic Macular Edema (DME) Market

15. Western Europe Diabetic Macular Edema (DME) Market

16. UK Diabetic Macular Edema (DME) Market

17. Germany Diabetic Macular Edema (DME) Market

18. France Diabetic Macular Edema (DME) Market

19. Italy Diabetic Macular Edema (DME) Market

20. Spain Diabetic Macular Edema (DME) Market

21. Eastern Europe Diabetic Macular Edema (DME) Market

22. Russia Diabetic Macular Edema (DME) Market

23. North America Diabetic Macular Edema (DME) Market

24. USA Diabetic Macular Edema (DME) Market

25. Canada Diabetic Macular Edema (DME) Market

26. South America Diabetic Macular Edema (DME) Market

27. Brazil Diabetic Macular Edema (DME) Market

28. Middle East Diabetic Macular Edema (DME) Market

29. Africa Diabetic Macular Edema (DME) Market

30. Diabetic Macular Edema (DME) Market Competitive Landscape And Company Profiles

31. Diabetic Macular Edema (DME) Market Other Major And Innovative Companies

32. Global Diabetic Macular Edema (DME) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Macular Edema (DME) Market

34. Recent Developments In The Diabetic Macular Edema (DME) Market

35. Diabetic Macular Edema (DME) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기